133 related articles for article (PubMed ID: 29429898)
1. Structural Basis for Inhibitor-Induced Hydrogen Peroxide Production by Kynurenine 3-Monooxygenase.
Kim HT; Na BK; Chung J; Kim S; Kwon SK; Cha H; Son J; Cho JM; Hwang KY
Cell Chem Biol; 2018 Apr; 25(4):426-438.e4. PubMed ID: 29429898
[TBL] [Abstract][Full Text] [Related]
2. Kynurenine 3-monooxygenase from Pseudomonas fluorescens: substrate-like inhibitors both stimulate flavin reduction and stabilize the flavin-peroxo intermediate yet result in the production of hydrogen peroxide.
Crozier-Reabe KR; Phillips RS; Moran GR
Biochemistry; 2008 Nov; 47(47):12420-33. PubMed ID: 18954092
[TBL] [Abstract][Full Text] [Related]
3. Biochemistry and structural studies of kynurenine 3-monooxygenase reveal allosteric inhibition by Ro 61-8048.
Gao J; Yao L; Xia T; Liao X; Zhu D; Xiang Y
FASEB J; 2018 Apr; 32(4):2036-2045. PubMed ID: 29208702
[TBL] [Abstract][Full Text] [Related]
4. Structural basis of kynurenine 3-monooxygenase inhibition.
Amaral M; Levy C; Heyes DJ; Lafite P; Outeiro TF; Giorgini F; Leys D; Scrutton NS
Nature; 2013 Apr; 496(7445):382-5. PubMed ID: 23575632
[TBL] [Abstract][Full Text] [Related]
5. Hydrogen movements in the oxidative half-reaction of kynurenine 3-monooxygenase from Pseudomonas fluorescens reveal the mechanism of hydroxylation.
Beaupre BA; Reabe KR; Roman JV; Moran GR
Arch Biochem Biophys; 2020 Sep; 690():108474. PubMed ID: 32687799
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore-Based Virtual Screening of Novel Competitive Inhibitors of the Neurodegenerative Disease Target Kynurenine-3-Monooxygenase.
Gotina L; Seo SH; Kim CW; Lim SM; Pae AN
Molecules; 2021 May; 26(11):. PubMed ID: 34073016
[TBL] [Abstract][Full Text] [Related]
7. Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase.
Hutchinson JP; Rowland P; Taylor MRD; Christodoulou EM; Haslam C; Hobbs CI; Holmes DS; Homes P; Liddle J; Mole DJ; Uings I; Walker AL; Webster SP; Mowat CG; Chung CW
Nat Commun; 2017 Jun; 8():15827. PubMed ID: 28604669
[TBL] [Abstract][Full Text] [Related]
8. Heterologous expression and purification of kynurenine-3-monooxygenase from Pseudomonas fluorescens strain 17400.
Crozier KR; Moran GR
Protein Expr Purif; 2007 Feb; 51(2):324-33. PubMed ID: 16973376
[TBL] [Abstract][Full Text] [Related]
9. Kynurenine-3-monooxygenase: a review of structure, mechanism, and inhibitors.
Smith JR; Jamie JF; Guillemin GJ
Drug Discov Today; 2016 Feb; 21(2):315-24. PubMed ID: 26589832
[TBL] [Abstract][Full Text] [Related]
10. Substrate and inhibitor specificity of kynurenine monooxygenase from Cytophaga hutchinsonii.
Phillips RS; Anderson AD; Gentry HG; Güner OF; Bowen JP
Bioorg Med Chem Lett; 2017 Apr; 27(8):1705-1708. PubMed ID: 28302400
[TBL] [Abstract][Full Text] [Related]
11. The Kynurenine Pathway and Kynurenine 3-Monooxygenase Inhibitors.
Hughes TD; Güner OF; Iradukunda EC; Phillips RS; Bowen JP
Molecules; 2022 Jan; 27(1):. PubMed ID: 35011505
[TBL] [Abstract][Full Text] [Related]
12. N-(6-phenylpyridazin-3-yl)benzenesulfonamides as highly potent, brain-permeable, and orally active kynurenine monooxygenase inhibitors.
Kimura H; Suda H; Kassai M; Endo M; Deai Y; Yahata M; Miyajima M; Isobe Y
Bioorg Med Chem Lett; 2021 Feb; 33():127753. PubMed ID: 33359168
[TBL] [Abstract][Full Text] [Related]
13. Modification of kynurenine pathway via inhibition of kynurenine hydroxylase attenuates surgical brain injury complications in a male rat model.
Zakhary G; Sherchan P; Li Q; Tang J; Zhang JH
J Neurosci Res; 2020 Jan; 98(1):155-167. PubMed ID: 31257634
[TBL] [Abstract][Full Text] [Related]
14. Increasing kynurenine brain levels reduces ethanol consumption in mice by inhibiting dopamine release in nucleus accumbens.
Giménez-Gómez P; Pérez-Hernández M; Gutiérrez-López MD; Vidal R; Abuin-Martínez C; O'Shea E; Colado MI
Neuropharmacology; 2018 Jun; 135():581-591. PubMed ID: 29705534
[TBL] [Abstract][Full Text] [Related]
15. Development of a Surface Plasmon Resonance Assay for the Characterization of Small-Molecule Binding Kinetics and Mechanism of Binding to Kynurenine 3-Monooxygenase.
Poda SB; Kobayashi M; Nachane R; Menon V; Gandhi AS; Budac DP; Li G; Campbell BM; Tagmose L
Assay Drug Dev Technol; 2015 Oct; 13(8):466-75. PubMed ID: 26292018
[TBL] [Abstract][Full Text] [Related]
16. Full-length in meso structure and mechanism of rat kynurenine 3-monooxygenase inhibition.
Mimasu S; Yamagishi H; Kubo S; Kiyohara M; Matsuda T; Yahata T; Thomson HA; Hupp CD; Liu J; Okuda T; Kakefuda K
Commun Biol; 2021 Feb; 4(1):159. PubMed ID: 33542467
[TBL] [Abstract][Full Text] [Related]
17. Advantages of brain penetrating inhibitors of kynurenine-3-monooxygenase for treatment of neurodegenerative diseases.
Zhang S; Collier MEW; Heyes DJ; Giorgini F; Scrutton NS
Arch Biochem Biophys; 2021 Jan; 697():108702. PubMed ID: 33275878
[TBL] [Abstract][Full Text] [Related]
18. Kynurenine-3-monooxygenase (KMO): From its biological functions to therapeutic effect in diseases progression.
Chen Y; Zhang J; Yang Y; Xiang K; Li H; Sun D; Chen L
J Cell Physiol; 2022 Dec; 237(12):4339-4355. PubMed ID: 36088660
[TBL] [Abstract][Full Text] [Related]
19. A magnetic bead-based ligand binding assay to facilitate human kynurenine 3-monooxygenase drug discovery.
Wilson K; Mole DJ; Homer NZ; Iredale JP; Auer M; Webster SP
J Biomol Screen; 2015 Feb; 20(2):292-8. PubMed ID: 25296660
[TBL] [Abstract][Full Text] [Related]
20. Development of LC/MS/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO).
Winkler D; Beconi M; Toledo-Sherman LM; Prime M; Ebneth A; Dominguez C; Muñoz-Sanjuan I
J Biomol Screen; 2013 Sep; 18(8):879-89. PubMed ID: 23690293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
